Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Naïve patients with rheumatoid arthritis: A single-center prospective study at 1 year (the Keio First-Bio Cohort study)
Dive into the research topics of 'Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Naïve patients with rheumatoid arthritis: A single-center prospective study at 1 year (the Keio First-Bio Cohort study)'. Together they form a unique fingerprint.